8月22日，燃石医学(BNR)盘中上涨2.53%，截至01:18，报9.535美元/股，成交9.03万美元，总市值1.03 亿美元。 财务数据显示，截至2025年03月31日，燃石医学收入总额1.33亿人民币，同比增长5.94%；归母净利 润-1350.0万人民币，同比增长88.89%。 作者：行情君 燃石医学于2018年7月获国家药品监督管理局(NMPA)颁发的中国肿瘤NGS检测试剂盒第一证,在体外诊 断领域具有里程碑式意义。位于中国广州的实验室通过广东省临床检验中心颁发的"高通量测序实验 室"技术审核,获得美国CLIA和CAP实验室质量体系资质认证;位于美国加利福尼亚州的实验室也已获得 CLIA和CAP实验室质量体系资质认证。公司将继续致力于开发创新可靠的NGS检测产品,推动肿瘤精准 医疗领域的发展。 本文源自：金融界 资料显示，燃石医学有限责任公司成立于2014年,公司使命为"用科学守护生命之光", 专注于为肿瘤精准 医疗提供具有临床价值的二代基因测序(NGS)。公司业务及研发方向主要覆盖:1)肿瘤患病人群检测,在 中国拥有领先的市场份额;2)全球抗肿瘤药企的生物标志物和伴随诊断合作;3)多癌种早检。 ...

Core Viewpoint - BNR's stock price surged by 30.88% on August 18, reaching $9.79 per share, with a total market capitalization of $105 million [1] Financial Performance - As of March 31, 2025, BNR reported total revenue of 133 million RMB, representing a year-on-year growth of 5.94% [1] - The net profit attributable to the parent company was -13.5 million RMB, showing a significant year-on-year improvement of 88.89% [1] Company Overview - BNR was established in 2014 with a mission to "guard the light of life with science," focusing on providing clinically valuable next-generation sequencing (NGS) for precision oncology [1] - The company's business and R&D directions primarily cover: 1) tumor patient population testing, holding a leading market share in China; 2) collaborations with global anti-tumor pharmaceutical companies for biomarkers and companion diagnostics; 3) early detection of multiple cancer types [1] Regulatory Milestones - In July 2018, BNR received the first certificate for NGS testing kits for tumors from the National Medical Products Administration (NMPA) in China, marking a milestone in the in vitro diagnostic field [2] - The laboratory in Guangzhou has passed the technical review by the Guangdong Provincial Clinical Testing Center and obtained quality system certifications from CLIA and CAP; the laboratory in California has also received CLIA and CAP certifications [2] - The company is committed to developing innovative and reliable NGS testing products to advance the field of precision oncology [2]

Core Insights - BNR's stock price increased by 5.35% to $7.88 per share, with a total market capitalization of $84.84 million as of August 18 [1] - For the fiscal year ending March 31, 2025, BNR reported total revenue of 133 million RMB, a year-on-year increase of 5.94%, and a net profit attributable to shareholders of -13.5 million RMB, reflecting a significant year-on-year improvement of 88.89% [1] Company Overview - BNR was established in 2014 with a mission to "guard the light of life with science," focusing on providing clinically valuable next-generation sequencing (NGS) for precision oncology [2] - The company's business and R&D directions include: 1) leading market share in tumor patient testing in China; 2) collaborations with global anti-tumor pharmaceutical companies for biomarkers and companion diagnostics; 3) early detection of multiple cancer types [2] - BNR received the first NGS testing kit certification for tumors from the National Medical Products Administration (NMPA) in July 2018, marking a milestone in the in vitro diagnostic field [2] - The laboratory in Guangzhou has passed the technical review by the Guangdong Provincial Clinical Testing Center and obtained quality system certifications from CLIA and CAP, while the laboratory in California has also received CLIA and CAP certifications [2] - The company is committed to developing innovative and reliable NGS testing products to advance the field of precision oncology [2]

8月28日，燃石医学将披露2025财年中报（数据来源于纳斯达克官网，预计披露日期为美国当地时间， 实际披露日期以公司公告为准）。 8月13日，燃石医学(BNR)盘中上涨2.98%，截至02:26，报7.147美元/股，成交5.21万美元，总市值 7694.67万美元。 财务数据显示，截至2025年03月31日，燃石医学收入总额1.33亿人民币，同比增长5.94%；归母净利 润-1350.0万人民币，同比增长88.89%。 大事提醒： 资料显示，燃石医学有限责任公司成立于2014年,公司使命为"用科学守护生命之光", 专注于为肿瘤精准 医疗提供具有临床价值的二代基因测序(NGS)。公司业务及研发方向主要覆盖:1)肿瘤患病人群检测,在 中国拥有领先的市场份额;2)全球抗肿瘤药企的生物标志物和伴随诊断合作;3)多癌种早检。 燃石医学于2018年7月获国家药品监督管理局(NMPA)颁发的中国肿瘤NGS检测试剂盒第一证,在体外诊 断领域具有里程碑式意义。位于中国广州的实验室通过广东省临床检验中心颁发的"高通量测序实验 室"技术审核,获得美国CLIA和CAP实验室质量体系资质认证;位于美国加利福尼亚州的实验室也已获得 C ...

8月8日，燃石医学(BNR)盘中上涨2.34%，截至23:12，报6.57美元/股，成交5.01万美元，总市值7073.65 万美元。 财务数据显示，截至2025年03月31日，燃石医学收入总额1.33亿人民币，同比增长5.94%；归母净利 润-1350.0万人民币，同比增长88.89%。 大事提醒： 资料显示，燃石医学有限责任公司成立于2014年,公司使命为"用科学守护生命之光", 专注于为肿瘤精准 医疗提供具有临床价值的二代基因测序(NGS)。公司业务及研发方向主要覆盖:1)肿瘤患病人群检测,在 中国拥有领先的市场份额;2)全球抗肿瘤药企的生物标志物和伴随诊断合作;3)多癌种早检。 燃石医学于2018年7月获国家药品监督管理局(NMPA)颁发的中国肿瘤NGS检测试剂盒第一证,在体外诊 断领域具有里程碑式意义。位于中国广州的实验室通过广东省临床检验中心颁发的"高通量测序实验 室"技术审核,获得美国CLIA和CAP实验室质量体系资质认证;位于美国加利福尼亚州的实验室也已获得 CLIA和CAP实验室质量体系资质认证。公司将继续致力于开发创新可靠的NGS检测产品,推动肿瘤精准 医疗领域的发展。 本文源自：金融界 ...

Core Insights - The stock price of Burning Stone Medical (BNR) increased by 5.25% on August 8, reaching $6.42 per share, with a total market capitalization of $69.12 million [1] - As of March 31, 2025, the total revenue of Burning Stone Medical was 133 million RMB, representing a year-on-year growth of 5.94%, while the net profit attributable to the parent company was -13.5 million RMB, showing a significant year-on-year increase of 88.89% [1] - The company is set to disclose its fiscal year 2025 mid-term report on August 28, with the actual disclosure date subject to company announcements [1] Company Overview - Burning Stone Medical was established in 2014, with a mission to "guard the light of life with science," focusing on providing clinically valuable next-generation sequencing (NGS) for precision oncology [1] - The company's business and research directions primarily cover: 1) detection of cancer patient populations, holding a leading market share in China; 2) collaboration with global anti-cancer pharmaceutical companies on biomarkers and companion diagnostics; 3) early detection of multiple cancer types [1] Regulatory Milestones - In July 2018, Burning Stone Medical received the first certificate for NGS testing kits for tumors from the National Medical Products Administration (NMPA) in China, marking a milestone in the field of in vitro diagnostics [2] - The laboratory located in Guangzhou, China, has passed the technical review by the Guangdong Provincial Clinical Testing Center and obtained quality system certifications from CLIA and CAP; the laboratory in California, USA, has also received CLIA and CAP certifications [2] - The company is committed to developing innovative and reliable NGS testing products to advance the field of precision oncology [2]

8月5日，燃石医学(BNR)盘中上涨2.31%，截至22:30，报6.295美元/股，成交1.42万美元，总市值 6777.57万美元。 财务数据显示，截至2025年03月31日，燃石医学收入总额1.33亿人民币，同比增长5.94%；归母净利 润-1350.0万人民币，同比增长88.89%。 燃石医学于2018年7月获国家药品监督管理局(NMPA)颁发的中国肿瘤NGS检测试剂盒第一证,在体外诊 断领域具有里程碑式意义。位于中国广州的实验室通过广东省临床检验中心颁发的"高通量测序实验 室"技术审核,获得美国CLIA和CAP实验室质量体系资质认证;位于美国加利福尼亚州的实验室也已获得 CLIA和CAP实验室质量体系资质认证。公司将继续致力于开发创新可靠的NGS检测产品,推动肿瘤精准 医疗领域的发展。 本文源自：金融界 作者：行情君 大事提醒： 8月28日，燃石医学将披露2025财年中报（数据来源于纳斯达克官网，预计披露日期为美国当地时间， 实际披露日期以公司公告为准）。 资料显示，燃石医学有限责任公司成立于2014年,公司使命为"用科学守护生命之光", 专注于为肿瘤精准 医疗提供具有临床价值的二代基因测序(NGS ...

Core Insights - The stock price of Burning Stone Medical (BNR) increased by 5.51% on July 30, reaching $6.13 per share, with a total market capitalization of $65.99 million [1] - As of March 31, 2025, the company's total revenue was 133 million RMB, reflecting a year-on-year growth of 5.94%, while the net profit attributable to the parent company was -13.5 million RMB, showing a significant year-on-year increase of 88.89% [1] - Burning Stone Medical is set to disclose its mid-year report for the fiscal year 2025 on August 28 [1] Company Overview - Burning Stone Medical was established in 2014, with a mission to "guard the light of life with science," focusing on providing clinically valuable next-generation sequencing (NGS) for precision oncology [1] - The company's business and research directions primarily cover: 1) detection of cancer patient populations, holding a leading market share in China; 2) collaboration with global anti-cancer pharmaceutical companies on biomarkers and companion diagnostics; 3) early detection of multiple cancer types [1] Regulatory Milestones - In July 2018, Burning Stone Medical received the first certificate for NGS testing kits for tumors from the National Medical Products Administration (NMPA) in China, marking a milestone in the field of in vitro diagnostics [2] - The laboratory located in Guangzhou, China, has passed the technical review by the Guangdong Provincial Clinical Testing Center and has obtained quality system certifications from CLIA and CAP; the laboratory in California, USA, has also received CLIA and CAP certifications [2] - The company is committed to developing innovative and reliable NGS testing products to advance the field of precision oncology [2]

Core Insights - The stock price of Burning Stone Medical (BNR) increased by 2.81% to $3.66 per share, with a total market capitalization of approximately $39.41 million as of July 8 [1] - For the fiscal year ending March 31, 2025, the company reported total revenue of 133 million RMB, reflecting a year-on-year growth of 5.94%, while the net profit attributable to shareholders was -13.5 million RMB, showing a significant year-on-year improvement of 88.89% [1] - Burning Stone Medical is set to release its mid-year report for the fiscal year 2025 on August 28, with the actual disclosure date subject to company announcements [1] Company Overview - Founded in 2014, Burning Stone Medical focuses on providing clinically valuable next-generation sequencing (NGS) for precision oncology, with a mission to "guard the light of life with science" [1] - The company's business and research directions include: 1) detection for cancer patients, holding a leading market share in China; 2) collaborations with global anti-cancer pharmaceutical companies for biomarkers and companion diagnostics; 3) early detection of multiple cancer types [1] Regulatory Milestones - In July 2018, Burning Stone Medical received the first NGS testing kit certification for tumors from the National Medical Products Administration (NMPA) in China, marking a significant milestone in the in vitro diagnostic field [2] - The laboratory in Guangzhou has passed the technical review by the Guangdong Provincial Clinical Testing Center and has obtained quality system certifications from CLIA and CAP in the United States [2] - The laboratory located in California has also received CLIA and CAP certifications, indicating the company's commitment to developing innovative and reliable NGS testing products to advance the field of precision oncology [2]

Core Insights - The stock price of Burning Stone Medical (BNR) increased by 7.38% on June 5, reaching $3.2 per share, with a total market capitalization of $34.45 million [1] - As of December 31, 2024, the company's total revenue is projected to be 516 million RMB, a year-on-year decrease of 4.02%, while the net profit attributable to the parent company is expected to be -347 million RMB, reflecting a year-on-year increase of 46.97% [1] Company Overview - Burning Stone Medical was established in 2014, with a mission to "protect the light of life with science," focusing on providing clinically valuable next-generation sequencing (NGS) for precision oncology [2] - The company's business and research directions primarily cover: 1) detection of cancer patient populations, holding a leading market share in China; 2) collaboration with global anti-cancer pharmaceutical companies on biomarkers and companion diagnostics; 3) early detection of multiple cancer types [2] - The company received the first NGS testing kit certification for tumors from the National Medical Products Administration (NMPA) in July 2018, marking a milestone in the field of in vitro diagnostics [2] - The laboratory located in Guangzhou, China, has passed the technical review by the Guangdong Provincial Clinical Testing Center and obtained quality system certifications from CLIA and CAP; the laboratory in California, USA, has also received CLIA and CAP certifications [2] - The company is committed to developing innovative and reliable NGS testing products to advance the field of precision oncology [2]